LUPIN
One of the few Indian generics makers with real strength in complex respiratory devices: it won early US approval for a generic dry powder inhaler competing with Boehringer Ingelheim's Spiriva, technology far harder to copy than a tablet. That capability sits alongside a history of US FDA warning letters across multiple plants, a recurring compliance strain many of its peers also face.
Pharmaceuticals - Generics & Respiratory
Generic and branded prescription drugs, complex inhalers and other respiratory devices, active pharmaceutical ingredients, and a large India-focused portfolio in anti-tuberculosis, diabetes, cardiovascular and respiratory medicine.
Mostly patients through pharmacies and hospitals, both in India under its own brands and in the US and other markets through generic drug distributors and health plans.
Sells branded drugs at a premium in India and generic versions of off-patent drugs at thin margins in the US and other regulated markets. Profit depends heavily on how many new generics it can launch, US price competition, and whether its plants keep passing FDA inspections.
The options-implied volatility comes from the live chain, which is available during and around market hours (9:15-3:30 IST, Mon-Fri). The stock has realized 13.5% volatility over the last 30 days; the implied figure and the comparison will show when the chain is live.
Loading LUPIN price...
LUPIN's live option chain - put-call ratio, max pain, expected move and open-interest walls - appears during market hours (9:15-3:30 IST, Mon-Fri). Come back when the market is open for the full options view.
Companies file a balance sheet twice a year, not every quarter, so this is the most recent one published rather than the latest quarter.
Cash flow is reported for the year to date, so this covers the full period ending 2026-03-31 rather than a single quarter.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
Operating margin has gone from 1.7% to 31.5% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.
2026 has paid Rs 18.00 per share, about Rs 859 on Rs 1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Insider trading data unavailable.
Announcements unavailable.
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.